Evidence map›Paper›PMID 35929474›Full record

Trial reportJournal of the American Heart Association2022

DR-FLASH Score Is Useful for Identifying Patients With Persistent Atrial Fibrillation Who Require Extensive Catheter Ablation Procedures.

Taiki Sato, Yohei Sotomi, Shungo Hikoso, Daisaku Nakatani, Hiroya Mizuno, Katsuki Okada, Tomoharu Dohi, Tetsuhisa Kitamura, Akihiro Sunaga, Hirota Kida and 15 more

Abstract readMulticenter StudyRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Taiki SatoDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Yohei SotomiDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Shungo HikosoDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.ORCID 0000-0003-2284-1970
Daisaku NakataniDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Hiroya MizunoDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Katsuki OkadaDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.ORCID 0000-0002-1725-781X
Tomoharu DohiDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.ORCID 0000-0003-1652-6421
Tetsuhisa KitamuraDepartment of Social and Environmental Medicine Osaka University Graduate School of Medicine Osaka Japan.
Akihiro SunagaDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.ORCID 0000-0003-2590-6696
Hirota KidaDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Bolrathanak OeunDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Yasuyuki EgamiDivision of Cardiology Osaka Rosai Hospital Sakai Japan.ORCID 0000-0001-9728-6524
Tetsuya WatanabeDivision of Cardiology Osaka General Medical Center Osaka Japan.ORCID 0000-0003-3979-527X
Hitoshi MinamiguchiDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Miwa MiyoshiDepartment of Cardiology, Osaka Hospital Japan Community Healthcare Organization Osaka Japan.
Nobuaki TanakaCardiovascular Center Sakurabashi Watanabe Hospital Osaka Japan.
Takafumi OkaDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Masato OkadaCardiovascular Center Sakurabashi Watanabe Hospital Osaka Japan.
Takashi KandaCardiovascular Center Kansai Rosai Hospital Amagasaki Japan.
Yasuhiro MatsudaCardiovascular Center Kansai Rosai Hospital Amagasaki Japan.
Masato KawasakiDivision of Cardiology Osaka General Medical Center Osaka Japan.
Masaharu MasudaCardiovascular Center Kansai Rosai Hospital Amagasaki Japan.
Koichi InoueCardiovascular Center Sakurabashi Watanabe Hospital Osaka Japan.
Yasushi SakataDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Osaka Cardio Vascular Conference (OCVC)‐Arrhythmia Investigators *

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Modification of arrhythmogenic substrates with extensive ablation comprising linear and/or complex fractional atrial electrogram ablation in addition to pulmonary vein isolation (PVI-plus) can theoretically reduce the recurrence of atrial fibrillation. The DR-FLASH score (score based on diabetes mellitus, renal dysfunction, persistent form of atrial fibrillation, left atrialdiameter >45 mm, age >65 years, female sex, and hypertension) is reportedly useful for identifying patients with arrhythmogenic substrates. We hypothesized that, in patients with persistent atrial fibrillation, the DR-FLASH score can be used to classify patients into those who require PVI-plus and those for whom a PVI-only strategy is sufficient. Methods and Results This study is a post hoc subanalysis of the a multicenter, randomized controlled, noninferiority trial investigating efficacy and safety of pulmonary vein isolation alone for recurrence prevention compared with extensive ablation in patients with persistent atrial fibrillation (EARNEST-PVI trial). This analysis focuses on the relationship between DR-FLASH score and the efficacy of different ablation strategies. We divided the population into 2 groups based on a DR-FLASH score of 3 points. A total of 469 patients were analyzed. Among those with a DR-FLASH score >3 (N=279), the event rate of atrial arrhythmia recurrence was significantly lower in the PVI-plus arm than in the PVI-only arm (hazard ratio [HR], 0.45 [95% CI, 0.28-0.72];

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsAgedElectrophysiologic Techniques, CardiacFemaleHumansRecurrenceTreatment Outcomecatheter ablationDR‐FLASH scorepersistent atrial fibrillationstratification

Identifiers

PMID35929474
PMCPMC9496301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.